IDEAYA Biosciences, Inc.
$3.24B- Market cap
- $3.80B
- Debt
- +$84.13M
- Cash
- −$639.39M
Capital structure 98% equity / 2% debt · EV / Revenue 14.83x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: IDYA stock price at premium vs TDOC $39.38 current versus $1.03 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TDOC's multiple
Implied fair value · at IDYA's multiple
Snapshot Sep 8, 2026, 2:14 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: IDYA FY 2025 (ended Dec 31, 2025) · TDOC FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 14.83x
Capital structure 53% equity / 47% debt · EV / Revenue 0.56x · EV / EBITDA 4.78x
IDYA carries the larger enterprise value at $3.24B against $1.41B; TDOC trades on the lower EV / Revenue multiple (0.56x vs 14.83x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
IDEAYA Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
TELADOC HEALTH, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.08x
0.75x
Net debt / EBITDA
Leverage against operating earnings
4.97x
0.87x
Cash and equivalents
Liquid reserves on the balance sheet
$639.39M
$781.08M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zentalis Pharmaceuticals, Inc.
IDYA vs ZNTL
Blueprint Medicines Corp
IDYA vs BPMC
Jazz Pharmaceuticals plc
IDYA vs JAZZ
Sarepta Therapeutics, Inc.
IDYA vs SRPT
Hims & Hers Health, Inc.
IDYA vs HIMS
GoodRx Holdings, Inc.
IDYA vs GDRX
Cigna Group
IDYA vs CI
VEEVA SYSTEMS INC
IDYA vs VEEV
$84.13M
$1.04B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.